Damora Therapeutics, Inc.

For the period ended Mar 31, 2025. Filed May 8, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 8, 2025

DMRA$24.15+0.3%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Statements of Cash Flows

(in thousands)

	Three Months Ended
	March 31,
	2025	2024
Cash flows from operating activities:
Net loss	$(2,533)	$(5,477)
Adjustment to reconcile net loss to net cash used in operating activities:
Depreciation	5	5
Stock-based compensation	179	1,359
Issuance of common stock in connection with vesting of restricted stock units	29	—
Amortization of premiums and discounts on marketable securities	—	(12)
Amortization of right of use lease asset	3	93
Accretion of lease liability	1	4
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(323)	252
Other assets, noncurrent	(151)	(582)
Accounts payable	(23)	(37)
Accrued expenses and other current liabilities	377	(1,449)
Operating lease liabilities	(5)	(92)
Other liabilities, noncurrent	2	—
Net cash used in operating activities	(2,439)	(5,936)
Cash flows from investing activities:
Proceeds from sale of marketable securities	—	5,650
Net cash provided by investing activities	—	5,650
Net decrease in cash and cash equivalents	(2,439)	(286)
Effect of exchange rate changes on cash and cash equivalents	203	(88)
Cash and cash equivalents, beginning of period	14,175	21,465
Cash and cash equivalents, end of period	$11,939	$21,091
Supplemental disclosures of cash flow information:
Cash paid for taxes	$2	$—

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.